Inveready leads €3.5m round for Leukos Biotech

Inveready drew capital from its Inveready Innvierte Biotech II vehicle. As part of the deal, two representatives from Inveready will take seats on the company's management board.

The company intends to use the capital injection to cover the costs of the second phase of its product development, which will consist of a clinical trial for patients over 60 years old, unfit for a bone marrow transplant or chemotherapy.

Moreover, the business aims to increase its workforce and move its research plant to the Barcelona Science Park.

Company
Founded in 2015 and headquartered in Barcelona, Leukos develops a drug that targets leukemia stem cells. The company employs a staff of three.

People
Inveready – Ignacio Fonts, Josep Maria Echarri (managing partners).
Leukos Biotech – Enrique Llaudet (CEO).

Advisers
Company – Antares Consulting (M&A); Jiménez de Parga Abogado (legal); Lexcrea (legal); RatnerPrestia (legal); Viraudit (tax).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Healthcare
• Southern Europe
• Spain